|By Business Wire||
|June 12, 2014 11:25 AM EDT||
Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that NUVISAN Pharma Services (“NUVISAN”) has purchased the ALPHADAS® clinical trials software solution suite for deployment in its Phase I unit located in Neu-Ulm, Germany.
NUVISAN is a fully integrated contract research organization providing clinical development and lab services to the global pharmaceutical industry. For over 30 years, NUVISAN has been assisting their clients in bringing safe and effective pharmaceutical products to market through its complete spectrum of services and the long-standing experience of their staff.
Following a competitive evaluation of commercial software systems and vendors, NUVISAN selected Instem’s ALPHADAS software suite based on its ability to support their clinical development team’s specific needs through flexible configurations, the ability to integrate with other support systems through the unit and for Instem’s rapid deployment services.
In addition to improving processes at their Phase I unit, ALPHADAS will be integrating with NUVISAN’s central lab operations resulting in enhanced quality and consistency while simultaneously improving efficiencies and saving time.
“Following a thorough evaluation of several software solutions, and after visiting with clients of each vendor under consideration, it was clear that ALPHADAS by Instem would not only be replacing our existing system, but was the one solution that would truly be providing us with the platform we need to help our clients succeed,” comments James Dickinson, Head of NUVISAN’s Phase I unit. “In addition to the technology, Instem is a well-respected, stable organization offering NUVISAN true subject matter expertise by staff that have run Phase I labs themselves. Bringing more than just software to us was an essential driver behind our decision and we are looking forward to a quick and efficient rollout of their system.”
Instem’s ALPHADAS software solution suite is a proactive early phase eSource data capture system with comprehensive CTMS capabilities. ALPHADAS is mobile, schedule-driven, and provides real-time bedside or station based direct data capture that virtually eliminates paper-based data.
Access the full news announcement at: http://www.instem.com/news/articles/0614-nuvisan-pharma-services-selects-alphadas.html.
About NUVISAN Pharma Services
NUVISAN Pharma Services is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. NUVISAN delivers services ranging from a single test to fully integrated drug development programs.
More about NUVISAN can be found at www.nuvisan.com.
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum.
To learn more about Instem solutions and its mission, please visit www.instem.com.
Meeting clients at the intersection of investment & return™.
Cloud based infrastructure deployment is becoming more and more appealing to customers, from Fortune 500 companies to SMEs due to its pay-as-you-go model. Enterprise storage vendors are able to reach out to these customers by integrating in cloud based deployments; this needs adaptability and interoperability of the products confirming to cloud standards such as OpenStack, CloudStack, or Azure. As compared to off the shelf commodity storage, enterprise storages by its reliability, high-availabil...
Oct. 21, 2016 11:00 AM EDT Reads: 894
Oct. 21, 2016 10:50 AM EDT
Oct. 21, 2016 10:45 AM EDT Reads: 1,631
Oct. 21, 2016 10:30 AM EDT Reads: 1,215
Oct. 21, 2016 10:30 AM EDT Reads: 498
Oct. 21, 2016 10:15 AM EDT Reads: 1,367
Oct. 21, 2016 09:30 AM EDT Reads: 1,122
Oct. 21, 2016 09:30 AM EDT Reads: 410
Oct. 21, 2016 09:15 AM EDT Reads: 213
Oct. 21, 2016 08:45 AM EDT Reads: 11,114
Oct. 21, 2016 08:45 AM EDT Reads: 1,359
Oct. 21, 2016 08:15 AM EDT Reads: 1,834
Oct. 21, 2016 08:00 AM EDT Reads: 5,571
Oct. 21, 2016 07:45 AM EDT Reads: 3,728
Oct. 21, 2016 07:45 AM EDT Reads: 2,054